.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC13_Ixekizumab.Ixekizumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC13_Ixekizumab.Ixekizumab| name: | Ixekizumab | |
| ATC code: | L04AC13 | route: | subcutaneous |
| compartments: | 2 | |
| dosage: | 160 | mg |
| volume of distribution: | 7.11 | L |
| clearance: | 0.0161 | L/h |
| other parameters in model implementation | ||
Ixekizumab is a humanized IgG4 monoclonal antibody that selectively binds to interleukin-17A (IL-17A), a pro-inflammatory cytokine. It is used for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Ixekizumab is approved by regulatory agencies, including the FDA and EMA, for these indications.
Population pharmacokinetics in adult patients with moderate-to-severe plaque psoriasis. Parameters were evaluated following subcutaneous administration in both males and females, aged 18 to 75 years.
Zheng, M, et al., & Zheng, J (2023). Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 1, Single- and Multiple-Dose Study. Advances in therapy 40(9) 3804–3816. DOI:10.1007/s12325-023-02575-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37356077